BSX

SEC source: 0001225208-21-010273 · doc4.xml · nonDerivative · entry 1

Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,957

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-21-010270 · doc4.xml · derivative · entry 1

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,143

Underlying: Common Stock · 16,143 shares

Expires 2025-07-01

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common slock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant.

SEC source: 0001225208-21-009606 · doc4.xml · derivative · entry 3

Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,450 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase 18,450 shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-21-009606 · doc4.xml · nonDerivative · entry 2

Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,830

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-009606 · doc4.xml · nonDerivative · entry 1

Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,280

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-009506 · doc4.xml · nonDerivative · entry 1

Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,229

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.66 to $42.84, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-21-009468 · doc4.xml · derivative · entry 6

Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 7,901 shares

Expires 2024-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: Grant to the reporting person on December 1, 2014, of an option to purchase 17,901 shares of common stock.

SEC source: 0001225208-21-009468 · doc4.xml · nonDerivative · entry 4

Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,062

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.63 to $42.93, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-21-009468 · doc4.xml · nonDerivative · entry 3

Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-009467 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 174,537

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-009468 · doc4.xml · derivative · entry 5

Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2024-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to the reporting person on February 24, 2014, of an option to purchase 15,000 shares of common stock.

SEC source: 0001225208-21-009468 · doc4.xml · nonDerivative · entry 2

Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,062

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-009468 · doc4.xml · nonDerivative · entry 1

Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,062

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-009034 · doc4.xml · nonDerivative · entry 1

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,057

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-008789 · doc4.xml · derivative · entry 3

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,973 shares

Expires 2021-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-21-008789 · doc4.xml · nonDerivative · entry 2

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,711

SEC source: 0001225208-21-008789 · doc4.xml · nonDerivative · entry 1

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,030

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-21-008787 · doc4.xml · nonDerivative · entry 1

Mackey Edward F · CIK 0001632900 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,722

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.59 to $42.82, inclusive. The reporting person undertakes to provide upon requestby the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-21-008786 · doc4.xml · derivative · entry 4

Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,762 shares

Expires 2021-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-21-008786 · doc4.xml · nonDerivative · entry 2

Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,464

SEC source: 0001225208-21-008786 · doc4.xml · nonDerivative · entry 1

Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,160

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-21-008788 · doc4.xml · nonDerivative · entry 1

Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,869

F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.51 to $42.67, inclusive. The reporting person undertakes to provide upon request by theU.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-21-010501 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,081,822

SEC source: 0001225208-21-007894 · doc4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,806

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-21-007880 · doc4.xml · nonDerivative · entry 1

ROUX DAVID J · CIK 0001234273 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,768

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-21-007879 · doc4.xml · derivative · entry 1

LUDWIG EDWARD J · CIK 0001221783 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,436

Underlying: Common Stock · 4,763 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · shares: Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-21-007881 · doc4.xml · nonDerivative · entry 1

Sununu John E · CIK 0001458974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,918

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-21-007878 · doc4.xml · derivative · entry 1

JAMES DONNA · CIK 0001197735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,247

Underlying: Common Stock · 4,763 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · shares: Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-21-007877 · doc4.xml · derivative · entry 1

FUJIMORI YOSHIAKI · CIK 0001233160 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,874

Underlying: Common Stock · 4,763 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · shares: Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-21-007876 · doc4.xml · nonDerivative · entry 2

Dockendorff Charles J · CIK 0001400563 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,501

F2 · shares: Restricted stock granted in lieu of 75% of cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of $105,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-21-007876 · doc4.xml · nonDerivative · entry 1

Dockendorff Charles J · CIK 0001400563 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,062

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-21-007872 · doc4.xml · nonDerivative · entry 2

Connors Nelda J · CIK 0001478748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,088

F2 · shares: Restricted stock granted in lieu of 50% of cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of $57,500, divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-21-007872 · doc4.xml · nonDerivative · entry 1

Connors Nelda J · CIK 0001478748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,753

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-21-010900 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Interven Cardio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,780

SEC source: 0001225208-21-007475 · doc4.xml · derivative · entry 3

Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,124

Underlying: Common Stock · 2,061 shares

Expires 2023-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant.

SEC source: 0001225208-21-007475 · doc4.xml · nonDerivative · entry 2

Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,830

SEC source: 0001225208-21-007475 · doc4.xml · nonDerivative · entry 1

Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,435

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-21-007384 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,134

SEC source: 0001225208-21-007384 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,920

SEC source: 0001225208-21-007382 · doc4.xml · nonDerivative · entry 2

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,859

SEC source: 0001225208-21-007382 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,217

F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.41 to $43.92, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-21-007238 · doc4.xml · derivative · entry 3

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 48,439 shares

Expires 2023-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.

SEC source: 0001225208-21-007238 · doc4.xml · nonDerivative · entry 2

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,158

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-007238 · doc4.xml · nonDerivative · entry 1

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-006808 · doc4.xml · derivative · entry 4

Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,250

Underlying: Common Stock · 4,250 shares

Expires 2024-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.

SEC source: 0001225208-21-006808 · doc4.xml · nonDerivative · entry 2

Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,398

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-006808 · doc4.xml · nonDerivative · entry 1

Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,074

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-006807 · doc4.xml · derivative · entry 3

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,123 shares

Expires 2022-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase 28,123 shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant.

SEC source: 0001225208-21-006807 · doc4.xml · nonDerivative · entry 2

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,158

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $40.95 and $40.955. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-21-006807 · doc4.xml · nonDerivative · entry 1

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,281

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.